Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
09:52:03 EDT Sat 04 May 2024
Enter Symbol
or Name
USA
CA



Q:TCON - TRACON PHARMACEUTICALS INC - http://www.traconpharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
TCON - Q2.01.80·1.920.41.86+0.052.8261.74431,5851.82  1.935  1.803315.294  1.5918:44:15Apr 0815 min RT 2¢

Recent Trades - Last 10 of 1585
Time ETExPriceChangeVolume
18:44:15Q1.840.031
18:43:47Q1.840.031
18:43:36Q1.840.031
18:43:26Q1.840.031
18:43:14Q1.840.031
18:42:58Q1.840.031
18:02:00Q1.840.03800
17:58:12Q1.840.031
17:57:11Q1.840.031
17:56:40Q1.840.031

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-08 09:10U:TCONNews ReleaseTRACON Pharmaceuticals Announces Reverse Stock Split
2024-04-03 08:00U:TCONNews ReleaseTRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned
2024-03-05 16:02U:TCONNews ReleaseTRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
2024-02-28 16:02U:TCONNews ReleaseTRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024
2023-12-20 08:00U:TCONNews ReleaseTRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial
2023-11-20 08:00U:TCONNews ReleaseTRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment
2023-11-09 16:02U:TCONNews ReleaseTRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-10-31 16:02U:TCONNews ReleaseTRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023
2023-09-18 08:00U:TCONNews ReleaseTRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
2023-09-05 16:02U:TCONNews ReleaseTRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences
2023-08-14 16:02U:TCONNews ReleaseTRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
2023-08-02 16:05U:TCONNews ReleaseTRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023
2023-07-11 08:00U:TCONNews ReleaseTRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma
2023-06-20 08:00U:TCONNews ReleaseTRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial
2023-06-16 08:00U:TCONNews ReleaseTRACON Pharmaceuticals to Present at the Maxim Group Healthcare Virtual Conference
2023-06-15 08:00U:TCONNews ReleaseTRACON Pharmaceuticals Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma
2023-06-02 08:00U:TCONNews ReleaseTRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference
2023-05-30 08:00U:TCONNews ReleaseTRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual Meeting
2023-05-10 16:02U:TCONNews ReleaseTRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and ‚  Provides Corporate Update